Targeting LSD1 for acute myeloid leukemia (AML) treatment.

Abstract

Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently there are very limited therapeutic targets for AML treatment. Histone lysine specific demethylase 1 (LSD1) is highly expressed in many cancers, impedes the differentiation of cancer cells, promotes the proliferation, metastasis and invasion of cancer cells, and is associated with poor prognosis. Targeting LSD1 has been recognized as a promising strategy for AML treatment in recent years. Based on these features, in the review, we discussed the main epigenetic drugs targeting LSD1 for AML therapy. Thus, this review focuses on the progress of LSD1 inhibitors in AML treatment, particularly those such as tranylcypromine (TCP), ORY-1001, GSK2879552, and IMG-7289 in clinical trials. These inhibitors provide novel scaffolds for designing new LSD1 inhibitors. Besides, combined therapies of LSD1 inhibitors with other drugs for AML treatment are also highlighted.

• Authors: Shujing Zhang, Menghan Liu, Yongfang Yao, Bin Yu, Hongmin Liu
• Journal: Pharmacological research (Pharmacol Res) Vol. 164 Pg. 105335 (02 2021) ISSN: 1096-1186 [Electronic] Netherlands
• PMID: 33285227 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Histone Demethylases
• KDM1A protein, human

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Histone Demethylases (antagonists & inhibitors, metabolism)
• Humans
• Leukemia, Myeloid, Acute (drug therapy, metabolism)
• Molecular Targeted Therapy